Search results
Showing 136 to 150 of 1164 results for criteria
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]
Awaiting development Reference number: GID-TA11904 Expected publication date: TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]
Awaiting development Reference number: GID-TA11953 Expected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]
Awaiting development Reference number: GID-TA11912 Expected publication date: TBC
Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716]
Awaiting development Reference number: GID-TA11925 Expected publication date: TBC
AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]
Awaiting development Reference number: GID-TA11962 Expected publication date: TBC
CM-AT for behaviours associated with autism in children and young people [ID6731]
Awaiting development Reference number: GID-TA11955 Expected publication date: TBC
Awaiting development Reference number: GID-TA11910 Expected publication date: TBC
Awaiting development Reference number: GID-TA11921 Expected publication date: TBC
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]
Awaiting development Reference number: GID-TA11915 Expected publication date: TBC
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Awaiting development Reference number: GID-TA11926 Expected publication date: TBC
Awaiting development Reference number: GID-TA11965 Expected publication date: TBC
Awaiting development Reference number: GID-TA11931 Expected publication date: TBC
Awaiting development Reference number: GID-TA11914 Expected publication date: TBC